HC Wainwright & Co. Reiterates Buy on Galera Therapeutics, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Galera Therapeutics (NASDAQ:GRTX) and maintained a $6 price target.
July 17, 2023 | 10:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Galera Therapeutics (NASDAQ:GRTX) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $6.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Galera Therapeutics. The maintained price target of $6 indicates the firm's confidence in the stock's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100